Recurrent Glioblastoma, IDH-Wildtype Clinical Trials

10 recruitingLast updated: June 18, 2026

There are 10 actively recruiting recurrent glioblastoma, idh-wildtype clinical trials across 2 countries. Studies span Phase 1, Phase 2, Early Phase 1. Top locations include Rochester, Minnesota, United States, Chicago, Illinois, United States, Duarte, California, United States. Updated daily from ClinicalTrials.gov.


Recurrent Glioblastoma, IDH-Wildtype Trials at a Glance

10 actively recruiting trials for recurrent glioblastoma, idh-wildtype are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 1 with 7 trials, with the heaviest enrollment activity in Rochester, Chicago, and Duarte. Lead sponsors running recurrent glioblastoma, idh-wildtype studies include Mayo Clinic, National Cancer Institute (NCI), and Darell Bigner.

Browse recurrent glioblastoma, idh-wildtype trials by phase

Treatments under study

About Recurrent Glioblastoma, IDH-Wildtype Clinical Trials

Looking for clinical trials for Recurrent Glioblastoma, IDH-Wildtype? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Recurrent Glioblastoma, IDH-Wildtype trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Recurrent Glioblastoma, IDH-Wildtype clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Early Phase 1

Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-WildtypeGlioblastoma (GBM)Recurrent Glioblastoma+1 more
Beijing Tiantan Hospital5 enrolled2 locationsNCT07648823
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled42 locationsNCT06860594
Recruiting
Phase 1

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-Wildtype
City of Hope Medical Center24 enrolled1 locationNCT07544992
Recruiting
Phase 1Phase 2

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma
National Cancer Institute (NCI)97 enrolled36 locationsNCT05432804
Recruiting
Phase 1

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-WildtypeRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more
Northwestern University30 enrolled1 locationNCT06410248
Recruiting
Phase 2

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Glioblastoma, IDH-wildtypeRecurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-Wildtype+6 more
Mayo Clinic36 enrolled1 locationNCT07301268
Recruiting
Phase 1

Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy

Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-WildtypeAstrocytoma, Grade IV
Mayo Clinic20 enrolled1 locationNCT05789394
Recruiting
Phase 1Phase 2

A Clinical Trial of P134 Cells in Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-Wildtype
Tasly Pharmaceutical Group Co., Ltd26 enrolled1 locationNCT07318818
Recruiting
Phase 2

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-WildtypeRecurrent GliosarcomaHigh Grade Astrocytic Tumor
Mayo Clinic54 enrolled1 locationNCT05465954
Recruiting
Phase 1

D2C7-IT + 2141-V11 Combination Post-resection in rGBM

Recurrent Glioblastoma, IDH-Wildtype
Darell Bigner46 enrolled1 locationNCT06455605